Treatment and Management of MM with Amyloidosis

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 5.Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

EP: 6.Future of Bispecifics and CAR T in R/R MM

EP: 7.Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

EP: 8.Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 9.Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

EP: 10.Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

EP: 11.Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

EP: 12.Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

EP: 13.Insights From Augmented Hyper-CVAD (AHCVAD), a Pediatric-Inspired Regimen for Adults Younger Than 50 Years With ALL

EP: 14.Key Takeaways From ASH 2024

EP: 15.Looking Into the Future of AML Treatments

EP: 16.Looking Ahead For the Treatments of R/R MM

EP: 17.Recommendations For Future Clinical Trials in R/R MM

Now Viewing

EP: 18.Treatment and Management of MM with Amyloidosis

EP: 19.Highlighting the Key Takeaways From ASH 2024

Video content above is prompted by the following:

Treatment and Management of Multiple Myeloma With Amyloidosis – Insights From ASH 2024

The 2024 ASH conference highlighted key advancements in the treatment and management of MM with amyloidosis, emphasizing early diagnosis, risk stratification, and personalized therapy approaches.

Early Detection and Risk Stratification:

Early diagnosis remains critical to improving outcomes, with biomarkers and imaging playing a growing role.

Risk-adapted approaches help tailor treatment, considering cardiac and renal involvement.

Frontline Therapy:

Daratumumab-based regimens (eg, Dara-VCD, Dara-CyBorD) are preferred for newly diagnosed patients, showing improved hematologic and organ responses.

High-dose melphalan with autologous stem cell transplantation remains an option for eligible patients, although risk-benefit assessment is crucial.

Novel Agents and Combinations:

Emerging data support using BCMA-targeted therapies, including chimeric antigen receptor T cells and bispecific antibodies, particularly in relapsed/refractory cases.

Venetoclax shows promise in t(11;14)-positive amyloidosis, offering a targeted approach.

Supportive Care and Organ Protection:

Managing cardiac and renal complications remains a cornerstone of care.

Novel therapies aim to reduce amyloid burden and improve organ function.

Future Directions:

Ongoing clinical trials explore next-generation immunotherapies and combination strategies to enhance depth and durability of response.

Overall, a multidisciplinary, individualized approach remains essential for optimizing patient outcomes in MM with amyloidosis.